KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.1 billion.

  • Teva Pharmaceutical Industries' Cost of Revenue fell 251.3% to $2.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.3 billion, marking a year-over-year decrease of 188.68%. This contributed to the annual value of $8.3 billion for FY2025, which is 189.84% down from last year.
  • Teva Pharmaceutical Industries' Cost of Revenue amounted to $2.1 billion in Q4 2025, which was down 251.3% from $2.2 billion recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cost of Revenue peaked at $2.2 billion during Q3 2024, and registered a low of $1.9 billion during Q1 2022.
  • Its 5-year average for Cost of Revenue is $2.1 billion, with a median of $2.1 billion in 2025.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Cost of Revenue crashed by 1476.09% in 2021 and then surged by 920.46% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cost of Revenue (Quarter) stood at $2.1 billion in 2021, then increased by 3.07% to $2.1 billion in 2022, then decreased by 3.41% to $2.0 billion in 2023, then increased by 3.33% to $2.1 billion in 2024, then decreased by 2.51% to $2.1 billion in 2025.
  • Its Cost of Revenue was $2.1 billion in Q4 2025, compared to $2.2 billion in Q3 2025 and $2.1 billion in Q2 2025.